Anbio Biotechnology
NASDAQ:NNNN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
A
|
Anbio Biotechnology
NASDAQ:NNNN
|
3.2B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
69.4B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
38.4B EUR |
Loading...
|
Market Distribution
| Min | -222 027.4% |
| 30th Percentile | -2% |
| Median | 2.2% |
| 70th Percentile | 6% |
| Max | 85 055.6% |
Other Profitability Ratios
Anbio Biotechnology
Glance View
Anbio Biotechnology is a DE-based company operating in Biotechnology industry. The company is headquartered in Frankfurt, Hessen. The company went IPO on 2025-02-19. Anbio Biotechnology is a Germany-based company. The firm is primarily engaged in the manufacturing of In Vitro Diagnostic Substance.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Anbio Biotechnology is 48.3%, which is above its 3-year median of 41.3%.
Over the last 1 years, Anbio Biotechnology’s Net Margin has increased from 46.6% to 48.3%. During this period, it reached a low of 29% on Dec 1, 2024 and a high of 48.3% on Jul 30, 2025.
